ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Wolchok Describes Candidates for Ipilimumab

Jedd D. Wolchok, MD, PhD
Published: Thursday, Jun 16, 2011

Jedd D. Wolchok, MD, PhD From Memorial Sloan-Kettering Cancer Center describes candidates for ipilimumab.

Dr. Wolchok says many melanoma patients are candidates for ipilimumab, if they have unresectable stage III or stage IV disease. Patients with melanoma that has spread to a distant organ or that has spread to local lymph nodes but can't be surgically removed are patients who, by the current US label, are eligible. The patients who doctors should be careful in using this drug with have a history of autoimmune disease.
Jedd D. Wolchok, MD, PhD From Memorial Sloan-Kettering Cancer Center describes candidates for ipilimumab.

Dr. Wolchok says many melanoma patients are candidates for ipilimumab, if they have unresectable stage III or stage IV disease. Patients with melanoma that has spread to a distant organ or that has spread to local lymph nodes but can't be surgically removed are patients who, by the current US label, are eligible. The patients who doctors should be careful in using this drug with have a history of autoimmune disease.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x